- Home
- RXO vs HTFL Comparison
RXO vs HTFL Comparison
Compare RXO & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RXO | HTFL |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXO | HTFL |
|---|---|---|
| Price | $12.64 | $22.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $16.31 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $0.78 | $40.42 |
| Revenue Next Year | $6.58 | $22.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $20.13 |
| 52 Week High | $19.65 | $41.22 |
Technical Indicators
Market Signals| Indicator | RXO | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 38.21 |
| Support Level | $12.33 | $20.13 |
| Resistance Level | $16.97 | $32.52 |
| Average True Range (ATR) | 1.02 | 1.54 |
| MACD | -0.33 | 0.11 |
| Stochastic Oscillator | 2.97 | 15.74 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.